p53-Independent Effects of Set7/9 Lysine Methyltransferase on Metabolism of Non-Small Cell Lung Cancer Cells.
SETD7
Set7/9
glycolysis
metabolism
non-small cell lung cancer (NSCLC)
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
07
05
2021
accepted:
14
09
2021
entrez:
25
10
2021
pubmed:
26
10
2021
medline:
26
10
2021
Statut:
epublish
Résumé
Set7/9 is a lysine-specific methyltransferase, which regulates the functioning of both the histone and non-histone substrates, thereby significantly affecting the global gene expression landscape. Using microarray expression profiling, we have identified several key master regulators of metabolic networks, including c-Myc, that were affected by Set7/9 status. Consistent with this observation, c-Myc transcriptional targets-genes encoding the glycolytic enzymes hexokinase (HK2), aldolase (ALDOB), and lactate dehydrogenase (LDHA)-were upregulated upon Set7/9 knockdown (Set7/9KD). Importantly, we showed the short hairpin RNA (shRNA)-mediated attenuation of Set7/9 augmented c-Myc, GLUT1, HK2, ALDOA, and LDHA expression in non-small cell lung cancer (NSCLC) cell lines, not only at the transcriptional but also at the protein level. In line with this observation, Set7/9KD significantly augmented the membrane mitochondrial potential (MMP), glycolysis, respiration, and the proliferation rate of NSCLC cells. Importantly, all these effects of Set7/9 on cell metabolism were p53-independent. Bioinformatic analysis has shown a synergistic impact of Set7/9 together with either GLUT1, HIF1A, HK2, or LDHA on the survival of lung cancer patients. Based on these evidence, we hypothesize that Set7/9 can be an important regulator of energy metabolism in NSCLC.
Identifiants
pubmed: 34692483
doi: 10.3389/fonc.2021.706668
pmc: PMC8528242
doi:
Types de publication
Journal Article
Langues
eng
Pagination
706668Informations de copyright
Copyright © 2021 Daks, Shuvalov, Fedorova, Petukhov, Lezina, Zharova, Baidyuk, Khudiakov and Barlev.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Dev Cell. 2016 Apr 4;37(1):47-57
pubmed: 27046831
Biochem Biophys Res Commun. 2020 May 14;525(4):1018-1024
pubmed: 32178870
PLoS One. 2014 Mar 13;9(3):e91606
pubmed: 24626155
Anticancer Res. 2020 Feb;40(2):609-618
pubmed: 32014901
Sci Rep. 2017 Oct 18;7(1):13488
pubmed: 29044214
Oncotarget. 2016 Jan 26;7(4):3966-83
pubmed: 26701885
Biochem Biophys Res Commun. 2018 Jan 1;495(1):1233-1239
pubmed: 29175211
J Biol Chem. 2015 Jul 3;290(27):16607-18
pubmed: 25995453
Nucleic Acids Res. 2015 May 26;43(10):5081-98
pubmed: 25897119
Mol Cell. 2008 Feb 15;29(3):392-400
pubmed: 18280244
Oncogene. 2020 Sep;39(39):6139-6156
pubmed: 32839493
Chin J Cancer. 2011 Aug;30(8):526-39
pubmed: 21801601
J Cancer Res Clin Oncol. 2019 Apr;145(4):967-999
pubmed: 30825027
Biochem Biophys Res Commun. 2009 Mar 27;381(1):22-6
pubmed: 19351588
Mini Rev Med Chem. 2009 Aug;9(9):1084-101
pubmed: 19689405
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Front Oncol. 2019 Nov 15;9:1215
pubmed: 31803611
Future Sci OA. 2016 Jan 29;2(1):FSO84
pubmed: 28031935
Int J Mol Med. 2020 May;45(5):1616-1626
pubmed: 32323737
Annu Rev Cell Dev Biol. 2011;27:441-64
pubmed: 21985671
Oncotarget. 2017 Apr 4;8(14):23955-23977
pubmed: 28177894
Front Oncol. 2020 Jan 24;10:5
pubmed: 32038983
Sci Rep. 2015 Oct 05;5:14368
pubmed: 26435321
Signal Transduct Target Ther. 2018 Jul 13;3:19
pubmed: 30013796
Tumour Biol. 2016 Jul;37(7):9311-22
pubmed: 26779630
Geburtshilfe Frauenheilkd. 2019 Feb;79(2):184-188
pubmed: 30792548
Cell Mol Life Sci. 2014 Nov;71(22):4471-86
pubmed: 24875254
Cancer Cell. 2012 Mar 20;21(3):297-308
pubmed: 22439925
Genes Cancer. 2016 Nov;7(11-12):383-393
pubmed: 28191284
Epigenetics. 2013 Apr;8(4):361-72
pubmed: 23478572
Trends Biochem Sci. 2016 Mar;41(3):211-218
pubmed: 26778478
J Exp Clin Cancer Res. 2019 May 23;38(1):218
pubmed: 31122265
Oncotarget. 2015 Sep 22;6(28):25843-55
pubmed: 26317544
Chem Biol. 2011 Jan 28;18(1):111-20
pubmed: 21276944
Biochem Biophys Res Commun. 2021 Oct 1;572:41-48
pubmed: 34343833
J Biol Chem. 2004 Nov 19;279(47):49064-73
pubmed: 15317809
Metabolites. 2020 Jul 16;10(7):
pubmed: 32708822
J Exp Clin Cancer Res. 2010 Nov 22;29:151
pubmed: 21092188
Oncogene. 2019 Mar;38(12):2108-2122
pubmed: 30455429
Oncogene. 2015 Jul;34(29):3751-9
pubmed: 25263450
Mol Cell. 2008 May 9;30(3):336-47
pubmed: 18471979
Nature. 2004 Nov 18;432(7015):353-60
pubmed: 15525938
Cell Death Dis. 2020 Dec 11;11(12):1047
pubmed: 33311447
Proc Natl Acad Sci U S A. 2011 Feb 1;108(5):1925-30
pubmed: 21245319
Ann Glob Health. 2019 Jan 22;85(1):
pubmed: 30741509
Biochim Biophys Acta. 2015 Sep;1852(9):1971-80
pubmed: 26144048
Cell Death Differ. 2016 May;23(5):912
pubmed: 26915292
Cell Cycle. 2006 Jun;5(12):1308-12
pubmed: 16760670
J Cell Biol. 2011 Aug 22;194(4):551-65
pubmed: 21859860
Elife. 2016 May 05;5:
pubmed: 27146893
Asian Pac J Cancer Prev. 2018 Sep 26;19(9):2377-2390
pubmed: 30255690
Proc Natl Acad Sci U S A. 2009 Nov 10;106(45):18972-7
pubmed: 19864627
Mol Cell. 2001 Dec;8(6):1207-17
pubmed: 11779497
Cell Death Dis. 2020 Feb 26;11(2):151
pubmed: 32102992
Mol Cell. 2002 Jun;9(6):1201-13
pubmed: 12086618
Cell Death Differ. 2014 Dec;21(12):1889-99
pubmed: 25124555
FASEB J. 2015 Oct;29(10):4313-23
pubmed: 26116705
Oncol Rep. 2018 Oct;40(4):1863-1874
pubmed: 30106440
Cancers (Basel). 2021 Feb 12;13(4):
pubmed: 33673109